Eledon Pharmaceuticals, Inc. - Common Stock — 四半期キャッシュフロー (NASDAQ:ELDN)

Financials

総資産 177.41 M161.31 M144.91 M129.86 M169.01 M146.67 M 負債合計 59.27 M46.73 M38.88 M38.8 M32.23 M46.21 M 純資産合計 118.14 M114.58 M50.33 M35.36 M81.08 M44.76 M 負債および純資産合計 177.41 M161.31 M144.91 M129.86 M169.01 M146.67 M 有利子負債合計 —————— 純負債 ——————

ニュース

Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year?

EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug - NewcelX (NASDAQ:NCEL)

Leerink Partners、Eledon株にアウトパフォーム評価を継続、目標株価5ドル

Leerink Partners reiterates Outperform on Eledon stock at $5

Eledon、膵島移植試験でインスリン離脱を報告

Eledon reports insulin independence in islet transplant trial

NewcelXが1型糖尿病治療でEledonと提携

NewcelX partners with Eledon on type 1 diabetes therapy

Eledon Pharmaceuticals at Guggenheim Summit: Tegoprubart’s Promising Path

Eledon社、腎臓移植におけるtegoprubart治療の24カ月データで良好な結果を報告

Eledon reports positive 24-month kidney transplant data for tegoprubart

エレドンのテゴプルバート、腎臓移植試験で有望な結果を示す